Tarlatamab Alternatives Compared
| Tarlatamab | Etoposide | Durvalumab |
|
|---|
| Tarlatamab | Etoposide | Durvalumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Small Cell Lung Cancer. Tarlatamab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ovarian Cancer, Testicular Cancer, Cancer, Hodgkin's Lymphoma, Multiple Myeloma, Small Cell Lung Cancer. Etoposide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Non Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Tumor, Bladder Cancer, Hepatocellular Carcinoma, Endometrial Cancer. Durvalumab may also be used for purposes not... View more |
Related suggestions Small Cell Lung Cancer
|
|||||||
| More about Tarlatamab | More about Etoposide | More about Durvalumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Etoposide has an average rating of 7.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Durvalumab has an average rating of 7.5 out of 10 from a total of 8 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Tarlatamab side effects |
View all Etoposide side effects |
View all Durvalumab side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
Lower cost generic |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Etoposide prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Imdelltra | Etopophos, Toposar | Imfinzi | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
636 hours |
11 hours |
408 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 364 drugs are known to interact with Tarlatamab:
|
A total of 473 drugs are known to interact with Etoposide:
|
A total of 630 drugs are known to interact with Durvalumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
May 16, 2024 |
December 30, 1986 |
May 01, 2017 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.